Katie Wynne Selected Research

Oxyntomodulin

10/2010	The mechanism of action for oxyntomodulin in the regulation of obesity.
7/2010	PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
2/2008	Can gut hormones control appetite and prevent obesity?
11/2006	The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control.
8/2005	Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katie Wynne Research Topics

Disease

5	Obesity 10/2010 - 08/2005
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 08/2021 - 01/2020
3	Weight Loss (Weight Reduction) 10/2010 - 08/2005
3	Overweight 07/2010 - 08/2005
2	Neuralgia (Stump Neuralgia) 08/2021 - 01/2020
2	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2021 - 01/2021
2	Neoplasms (Cancer) 11/2019 - 01/2019
2	Body Weight (Weight, Body) 11/2006 - 08/2005
1	Birth Weight (Birth Weights) 01/2022
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2022
1	Hypoparathyroidism 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Pancreatitis 12/2020
1	Hypoglycemia (Reactive Hypoglycemia) 12/2020
1	Chronic Pain 01/2020
1	Diabetic Neuropathies (Diabetic Neuropathy) 01/2020
1	Hyperlipidemias (Hyperlipidemia) 01/2020
1	Thyroid Neoplasms (Thyroid Cancer) 11/2019
1	Pancreatic Diseases (Pancreatic Disease) 02/2019
1	Ketosis 02/2019
1	Hyperglycemia 02/2019
1	Hemochromatosis (Bronze Diabetes) 02/2019
1	Cystic Fibrosis (Mucoviscidosis) 02/2019
1	Chronic Pancreatitis 02/2019
1	Graves Disease (Basedow Disease) 01/2019
1	Inappropriate ADH Syndrome (SIADH) 02/2018
1	Thyroid Nodule (Nodule, Thyroid) 01/2016
1	Hyperthyroidism 01/2016
1	Papillary Thyroid Cancer 01/2016
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 05/2013
1	Chronic Kidney Failure (Chronic Renal Failure) 07/2005
1	Anorexia 07/2005
1	Malnutrition (Nutritional Deficiencies) 07/2005

Drug/Important Bio-Agent (IBA)

5	Hormones (Hormone)IBA 01/2022 - 07/2005
5	OxyntomodulinIBA 10/2010 - 08/2005
2	Insulin (Novolin)FDA Link 01/2021 - 12/2020
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2019
2	GhrelinIBA 02/2008 - 07/2005
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2022
1	SuspensionsIBA 08/2021
1	Parathyroid Hormone (Parathormone)IBA 01/2021
1	Cholecalciferol (Vitamin D3)FDA Link 01/2021
1	Vitamin D FDA LinkGeneric 01/2021
1	Betamethasone (Celestone)FDA Link 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Triglycerides (Triacylglycerol)IBA 12/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	CytokinesIBA 01/2020
1	sapropterin (tetrahydrobiopterin)FDA Link 01/2020
1	xanthurenic acidIBA 01/2020
1	KynurenineIBA 01/2020
1	kynurenine-oxoglutarate transaminaseIBA 01/2020
1	Nerve Growth Factor (NGF)IBA 11/2019
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2019
1	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA 02/2019
1	SaltsIBA 02/2018
1	IodineIBA 01/2016
1	Thyrotropin Receptors (Thyrotropin Receptor)IBA 01/2016
1	Glucagon (Glukagon)FDA Link 05/2013
1	Metyrapone FDA Link 05/2013
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 07/2010
1	Appetite Depressants (Anorectics)IBA 07/2010
1	Pancreatic Polypeptide (Pancreatic Polypeptide (PP))IBA 02/2008
1	Glucagon-Like Peptide 1 (GLP 1)IBA 02/2008
1	Peptide YYIBA 02/2008
1	Peptides (Polypeptides)IBA 11/2006
1	Serum AlbuminIBA 07/2005
1	CholesterolIBA 07/2005

Therapy/Procedure

5	Therapeutics 12/2020 - 07/2005
2	Thyroidectomy 01/2021 - 01/2019
1	Cesarean Section (Caesarean Section) 01/2022
1	Contraception (Birth Control) 01/2022
1	Peritoneal Dialysis 07/2005